A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women

International Journal of Endocrinology

Volumn 2016, Issue , 2016, Pages

  Benelli, Elena ^a   Del Ghianda, Scilla ^a   Di Cosmo, Caterina ^a   Tonacchera, Massimo ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; D CHIROINOSITOL; ESTRADIOL; FOLIC ACID; FOLLITROPIN; GLUCOSE; INOSITOL; INOSITOL DERIVATIVE; INSULIN; LUTEINIZING HORMONE; PLACEBO; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ANOVULATION; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; ENDOCRINE SYSTEM; FEMALE; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MEDICAL PARAMETERS; METABOLIC PARAMETERS; OBESITY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84979680831     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2016/3204083     Document Type: Article

References (43)

1. B. C. J. M. Fauser, "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, " Fertility and Sterility, vol. 81, no. 1, pp. 19-25, 2004.
2. "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), " Human Reproduction, vol. 19, pp. 41-47, 2004.
3. S. M. Sirmans and K. A. Pate, "Epidemiology, diagnosis, and management of polycystic ovary syndrome, " Clinical Epidemiology, vol. 6, no. 1, pp. 1-13, 2013.
4. T. M. Barber, M. I. McCarthy, J. A. H. Wass, andS. Franks, "Obesity and polycystic ovary syndrome, " Clinical Endocrinology, vol. 65, no. 2, pp. 137-145, 2006.
5. A. Podfigurna-Stopa, S. Luisi, C. Regini et al., "Mood disorders and quality of life in polycystic ovary syndrome, " Gynecological Endocrinology, vol. 31, no. 6, pp. 431-434, 2015.
6. G. A. Burghen, J. R. Givens, and A. E. Kitabchi, "Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, " Journal of Clinical Endocrinology & Metabolism, vol. 50, no. 1, pp. 113-116, 1980.
7. A. Dunaif and A. R. Hoffman, "Insulin resistance and hyperandrogenism: clinical syndromes and possible mechanisms, " in Biorhythms and Stress in the Physiopathology of Reproduction, P. Pancheri and L. Zichella, Eds., pp. 293-317, Hemisphere, Washington, DC, USA, 1988.
8. A. Dunaif, "Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis, " Endocrine Reviews, vol. 18, no. 6, pp. 774-800, 1997.
9. M. Ciampelli, A. M. Fulghesu, F. Cucinelli et al., "Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome, " Metabolism: Clinical and Experimental, vol. 48, no. 2, pp. 167-172, 1999.
10. A. Gambineri and R. Pasquali, "Insulin resistance, obesity and metabolic syndrome in polycystic ovary syndrome, " Endocrinologá y Nutricion, vol. 53, no. 1, pp. 41-55, 2006.
11. F. Álvarez-Blasco, J. I. Botella-Carretero, J. L. San Millán, and H. F. Escobar-Morreale, "Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women, " Archives of Internal Medicine, vol. 166, no. 19, pp. 2081-2086, 2006.
12. N. K. Stepto, S. Cassar, A. E. Joham et al., "Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp, " Human Reproduction, vol. 28, no. 3, pp. 777-784, 2013.
13. J. E. Nestler and J. F. Strauss III, "Insulin as an effector of human ovarian and adrenal steroid metabolism, " Endocrinology and MetabolismClinics of North America, vol. 20, no. 4, pp. 807-823, 1991.
14. J. C. Marshall and A. Dunaif, "Should all women with PCOS be treated for insulin resistance" Fertility and Sterility, vol. 97, no. 1, pp. 18-22, 2012.
15. J. E. Nestler, D. Stovall, N. Akhter, M. J. Iuorno, and D. J. Jakubowicz, "Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome, " Fertility and Sterility, vol. 77, no. 2, pp. 209-215, 2002.
16. V. De Leo, M. C. Musacchio, G. Morgante, P. Piomboni, and F. Petraglia, "Metformin treatment is effective in obese teenage girls with PCOS, " Human Reproduction, vol. 21, no. 9, pp. 2252-2256, 2006.
17. J. Larner, "D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance, " International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 47-60, 2002.
18. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, "Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome, " Gynecological Endocrinology, vol. 24, no. 3, pp. 139-144, 2008.
19. S. Gerli, M. Mignosa, and G. C. Di Renzo, "Effects of inositol on ovarian function and metabolic factors in women with PCOS: A randomized double blind placebo-controlled trial, " European Review for Medical and Pharmacological Sciences, vol. 7, no. 6, pp. 151-159, 2003.
20. M. Bizzarri andG. Carlomagno, "Inositol: history of an effective therapy for polycystic ovary syndrome, " European Review for Medical and Pharmacological Sciences, vol. 18, no. 13, pp. 1896-1903, 2014.
21. M. Minozzi, D. Costantino, C. Guaraldi, and V. Unfer, "The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome, " Gynecological Endocrinology, vol. 27, no. 11, pp. 920-924, 2011.
22. V. Unfer, G. Carlomagno, E. Papaleo, S. Vailati, M. Candiani, and J.-P. Baillargeon, "Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS, " Reproductive Sciences, vol. 21, no. 7, pp. 854-858, 2014.
23. D. Heimark, J. McAllister, and J. Larner, "Decreased myoinositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls, " Endocrine Journal, vol. 61, no. 2, pp. 111-117, 2014.
24. F. Facchinetti, G. Dante, and I. Neri, "The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences, " in Frontiers in Gynecological Endocrinology, Part of the series ISGE Series, pp. 103-109, Springer, Berlin, Germany, 2015.
25. A. Bevilacqua, G. Carlomagno, S. Gerli et al., "Results from the international consensus conference onmyo-inositol and Dchiro-inositol in obstetrics and gynecology-assisted reproduction technology, " Gynecological Endocrinology, vol. 31, no. 6, pp. 441-446, 2015.
26. F. Facchinetti, M. Bizzarri, S. Benvenga et al., "Results from the international consensus conference on myo-inositol and dchiro-inositol in obstetrics and gynecology: The link between metabolic syndrome and PCOS, " European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 195, pp. 72-76, 2015.
27. J.-P. Baillargeon, M. J. Iuorno, and J. E. Nestler, "Insulin sensitizers for polycystic ovary syndrome, " Clinical Obstetrics and Gynecology, vol. 46, no. 2, pp. 325-340, 2003.
28. J. E. Nestler, "Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications, " Seminars in Reproductive Endocrinology, vol. 15, no. 2, pp. 111-122, 1997.
29. A. D. Genazzani, C. Battaglia, B. Malavasi, C. Strucchi, F. Tortolani, and O. Gamba, "Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients withpolycystic ovary syndrome, " Fertility and Sterility, vol. 81, no. 1, pp. 114-119, 2004.
30. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, "Effects of myo-inositol in women with PCOS: A systematic review of randomized controlled trials, " Gynecological Endocrinology, vol. 28, no. 7, pp. 509-515, 2012.
31. A. Dunaif, "Insulin resistance in women with polycystic ovary syndrome, " Fertility and Sterility, vol. 86, supplement 1, pp. S13-S14, 2006.
32. R. Pasquali, C. Pelusi, C. Ragazzini, R. Hasanaj, and A. Gambineri, "Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome, " Journal of the Pancreas, vol. 3, no. 1, pp. 1-7, 2002.
33. D. Costantino, G. Minozzi, F. Minozzi, and C. Guaraldi, "Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: A double-blind trial, " European Review for Medical and Pharmacological Sciences, vol. 13, no. 2, pp. 105-110, 2009.
34. S. Gerli, E. Papaleo, A. Ferrari, and G. C. Di Renzo, "Randomized, double blind placebo-controlled trial: effects of myoinositol on ovarian function and metabolic factors in women with PCOS, " European Review forMedical and Pharmacological Sciences, vol. 11, no. 5, pp. 347-354, 2007.
35. A. S. Laganà, L. Barbaro, and A. Pizzo, "Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol, " Archives of Gynecology and Obstetrics, vol. 291, no. 5, pp. 1181-1186, 2015.
36. M. Nordio and E. Proietti, "The Combined therapy with myoinositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared tomyo-inositol supplementation alone, " European Review for Medical and Pharmacological Sciences, vol. 16, no. 5, pp. 575-581, 2012.
37. M. Minozzi, M. Nordio, and R. Pajalich, "The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients, " European Review for Medical and Pharmacological Sciences, vol. 17, no. 4, pp. 537-540, 2013.
38. L. C. Huang, M. C. Fonteles, D. B. Houston, C. Zhang, and J. Larner, "Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocindiabetic rats in vivo, " Endocrinology, vol. 132, no. 2, pp. 652-657, 1993.
39. T.-H. Sun, D. B. Heimark, T. Nguygen, J. L. Nadler, and J. Larner, "Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls, " Biochemical and Biophysical Research Communications, vol. 293, no. 3, pp. 1092-1098, 2002.
40. V. De Leo, G. Morgante, P. Piomboni, M. C. Musacchio, F. Petraglia, and A. Cianci, "Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome, " Fertility and Sterility, vol. 88, no. 1, pp. 113-117, 2007.
41. N. Cinar, A. Harmanci, M. Bayraktar, and B. O. Yildiz, "Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome, " Clinical Endocrinology, vol. 78, no. 3, pp. 379-384, 2013.
42. A. Van Hylckama Vlieg, F. M. Helmerhorst, J. P. Vandenbroucke, C. J. M. Doggen, and F. R. Rosendaal, "The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of theMEGA case-control study, " The British Medical Journal, vol. 339, Article ID b2921, 2009.
43. ACOG Committee on Practice Bulletins Gynecology, "ACOG Practice Bulletin No. 108: Polycystic ovary syndrome, " Obstetrics & Gynecology, vol. 114, no. 4, pp. 936-949, 2009.